The data demonstrate that SLC6A19 inhibition results in a dose-dependent increase in urinary excretion of amino acids, including phenylalanine (Phe), and lowers plasma Phe levels in a PKU mouse model.

MZE782 is a potential first-in-class, oral, small molecule therapy targeting SLC6A19 Proof of mechanism data anticipated 2H 2025 October 01, 2024 08:30 AM Eastern Daylight Time ...

Maze Therapeutics Inc. has disclosed new sodium-dependent neutral amino acid transporter B (0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, ...

Jnana Therapeutics Inc. has identified sodium-dependent neutral amino acid transporter B (0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, ...